Abdallah M, Alhababi R, Alqudah N, Aldyyat B, Alharthy A
Pharmaceutical Care Services, King Saud Medical City, Riyadh, Saudi Arabia.
Microbiology Department, King Saud Medical City, Riyadh, Saudi Arabia.
New Microbes New Infect. 2018 Sep 20;26:107-109. doi: 10.1016/j.nmni.2018.09.007. eCollection 2018 Nov.
We present the case of 31-year-old man who developed hospital-acquired pneumonia in the intensive care unit. Pathogens were identified to be carbapenem-resistant isolates of and The patient was treated with an extended infusion of double-dose meropenem (targeting the carbapenem-resistant ) and colistin (targeting the carbapenem-resistant ) for 2 weeks. The patient's disease responded well to the prescribed regimen; his chest X-ray became normal, and all other signs of infection subsided. To our knowledge, this is the first description of the emergence of carbapenem-resistant due to AmpC hyperproduction in Saudi Arabia.
我们报告了一名31岁男性在重症监护病房发生医院获得性肺炎的病例。病原体被鉴定为对碳青霉烯类耐药的分离株。患者接受了双倍剂量美罗培南延长输注（针对对碳青霉烯类耐药的菌株）和黏菌素（针对对碳青霉烯类耐药的菌株）治疗2周。患者的病情对规定的治疗方案反应良好；他的胸部X光片恢复正常，所有其他感染迹象也消退了。据我们所知，这是沙特阿拉伯首例因AmpC高产导致对碳青霉烯类耐药菌株出现的描述。
